ImmunoBiology Ltd
Cambridge, Cambridgeshire, United Kingdom
About ImmunoBiology Ltd
ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies. ImmBio is developing next-generation vaccines against serious infectious disease targets, utilising its proprietary technology platforms to directly induce immunity via dendritic cells. ImmBio's lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $5.1M
- Last round: Grant (Mar 2013)
- Website: immbio.net
- Phone: +44 (0)1223 496117
Industries & Categories
Biotechnology, Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/immunobiology-ltd-2511409 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.